Literature DB >> 35769968

Johanson-Blizzard's Syndrome with a Novel UBR1 Mutation.

Damla Demir1, Yasemin Kendir Demirkol2, Nelgin Gerenli3, Ezgi Aktaş Karabay4.   

Abstract

Johanson-Blizzard syndrome (JBS) is a rare autosomal recessive genetic disorder, characterized by exocrine pancreatic insufficiency, a distinct abnormal facial appearance and varying degrees of growth retardation. Ubiquitin protein ligase E3 component n-recognin 1 ( UBR1 ) gene mutations are responsible for the syndrome. Here, we describe a 2-month-old female infant, who presented with oily diarrhea, facial dysmorphia, scalp defect, hearing defects, and growth impairment. Molecular genetic testing revealed a novel frameshift mutation in UBR1 , c.4027_4028 del (p.Leu1343Valfs*7), which was not previously described in JBS in the literature. Thieme. All rights reserved.

Entities:  

Keywords:  Johanson–Blizzard's syndrome; UBR1 gene ; aplasia cutis; facial dysmorphia; novel variants; pancreatic insufficiency

Year:  2020        PMID: 35769968      PMCID: PMC9236751          DOI: 10.1055/s-0040-1716331

Source DB:  PubMed          Journal:  J Pediatr Genet        ISSN: 2146-460X


  12 in total

Review 1.  Genetic basis and pancreatic biology of Johanson-Blizzard syndrome.

Authors:  Martin Zenker; Julia Mayerle; André Reis; Markus M Lerch
Journal:  Endocrinol Metab Clin North Am       Date:  2006-06       Impact factor: 4.741

2.  Severe forms of Johanson-Blizzard syndrome caused by two novel compound heterozygous variants in UBR1: Clinical manifestations, imaging findings and molecular genetics.

Authors:  Shu Liu; Zhiqing Wang; Jianhui Jiang; Xianqiong Luo; Qingshan Hong; Ye Zhang; Haimei OuYang; Sisi Wei; Jinqun Liang; Nuan Chen; Weihong Zeng
Journal:  Pancreatology       Date:  2020-01-17       Impact factor: 3.996

Review 3.  The N-end rule pathway and regulation by proteolysis.

Authors:  Alexander Varshavsky
Journal:  Protein Sci       Date:  2011-08       Impact factor: 6.725

4.  A syndrome of congenital aplasia of the alae nasi, deafness, hypothyroidism, dwarfism, absent permanent teeth, and malabsorption.

Authors:  A Johanson; R Blizzard
Journal:  J Pediatr       Date:  1971-12       Impact factor: 4.406

5.  Two novel UBR1 gene mutations ın a patient with Johanson Blizzard Syndrome: A mild phenotype without mental retardation.

Authors:  Tahir Atik; Miray Karakoyun; Maja Sukalo; Martin Zenker; Ferda Ozkinay; Sema Aydoğdu
Journal:  Gene       Date:  2015-07-03       Impact factor: 3.688

6.  Novel UBR1 gene mutation in a patient with typical phenotype of Johanson-Blizzard syndrome.

Authors:  Gholam Hossein Fallahi; Mozhgan Sabbaghian; Manijeh Khalili; Nima Parvaneh; Martin Zenker; Nima Rezaei
Journal:  Eur J Pediatr       Date:  2010-06-17       Impact factor: 3.183

Review 7.  The N-end rule pathway.

Authors:  Takafumi Tasaki; Shashikanth M Sriram; Kyong Soo Park; Yong Tae Kwon
Journal:  Annu Rev Biochem       Date:  2012-04-10       Impact factor: 23.643

8.  Johanson-Blizzard syndrome with mild phenotypic features confirmed by UBR1 gene testing.

Authors:  Naim Alkhouri; Barbara Kaplan; Marsha Kay; Amy Shealy; Carol Crowe; Susanne Bauhuber; Martin Zenker
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

9.  Ubiquitin ligases of the N-end rule pathway: assessment of mutations in UBR1 that cause the Johanson-Blizzard syndrome.

Authors:  Cheol-Sang Hwang; Maja Sukalo; Olga Batygin; Marie-Claude Addor; Han Brunner; Antonio Perez Aytes; Julia Mayerle; Hyun Kyu Song; Alexander Varshavsky; Martin Zenker
Journal:  PLoS One       Date:  2011-09-13       Impact factor: 3.240

10.  Expanding the mutational spectrum in Johanson-Blizzard syndrome: identification of whole exon deletions and duplications in the UBR1 gene by multiplex ligation-dependent probe amplification analysis.

Authors:  Maja Sukalo; Eva Schäflein; Ina Schanze; David B Everman; Nima Rezaei; Jesús Argente; Isabel Lorda-Sanchez; Charu Deshpande; Tsutomu Takahashi; Alexander Kleger; Martin Zenker
Journal:  Mol Genet Genomic Med       Date:  2017-07-31       Impact factor: 2.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.